首页> 外文期刊>Primary care >Renin-Angiotensin-Aldosterone System Inhibition Overview of the Therapeutic Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Mineralocorticoid Receptor Antagonists, and Direct Renin Inhibitors
【24h】

Renin-Angiotensin-Aldosterone System Inhibition Overview of the Therapeutic Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, Mineralocorticoid Receptor Antagonists, and Direct Renin Inhibitors

机译:血管紧张素转换酶抑制剂,血管紧张素受体阻滞剂,盐皮质激素受体拮抗剂和直接肾素抑制剂治疗用途的肾素-血管紧张素-醛固酮系统抑制概述

获取原文
获取原文并翻译 | 示例
           

摘要

Angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy in hypertensive diabetic patients with macroalbuminuria, microalbuminuria, or normoalbuminuria has been repeatedly shown to improve cardiovascular mortality and reduce the decline in glomerular filtration rate. Renin-angiotensin-aldosterone system (RAAS) blockade in normotensive diabetic patients with normoalbuminuria or microalbuminuria cannot be advocated at present. Dual RAAS inhibition with ACE inhibitors plus ARBs or ACE inhibitors plus direct renin inhibitors has failed to improve cardiovascular or renal outcomes but has predisposed patients to serious adverse events.
机译:高血压糖尿病合并大白蛋白尿,微白蛋白尿或正常白蛋白尿的糖尿病患者的血管紧张素转换酶(ACE)抑制剂或血管紧张素受体阻滞剂(ARB)治疗已被反复证明可改善心血管疾病的死亡率并降低肾小球滤过率的下降。目前不能提倡正常血压性糖尿病伴正常白蛋白尿或微量白蛋白尿的患者的肾素-血管紧张素-醛固酮系统(RAAS)阻滞。用ACE抑制剂加ARB或ACE抑制剂加直接肾素抑制剂双重抑制RAAS并不能改善心血管或肾脏的预后,但使患者容易发生严重的不良事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号